MX2023013410A - Terapias de combinacion. - Google Patents
Terapias de combinacion.Info
- Publication number
- MX2023013410A MX2023013410A MX2023013410A MX2023013410A MX2023013410A MX 2023013410 A MX2023013410 A MX 2023013410A MX 2023013410 A MX2023013410 A MX 2023013410A MX 2023013410 A MX2023013410 A MX 2023013410A MX 2023013410 A MX2023013410 A MX 2023013410A
- Authority
- MX
- Mexico
- Prior art keywords
- effective amount
- formula
- combinations
- therapeutically effective
- combination therapies
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- SRQYLNYQAPCPIR-UHFFFAOYSA-N 4-[4-(5,5-dimethyl-4H-thiazol-2-yl)-1-piperazinyl]-6-propylthieno[2,3-d]pyrimidine Chemical compound N1=CN=C2SC(CCC)=CC2=C1N(CC1)CCN1C1=NCC(C)(C)S1 SRQYLNYQAPCPIR-UHFFFAOYSA-N 0.000 abstract 1
- 239000012664 BCL-2-inhibitor Substances 0.000 abstract 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 abstract 1
- 229940119544 Menin-MLL inhibitor Drugs 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021093036 | 2021-05-11 | ||
| CN2021100523 | 2021-06-17 | ||
| CN2022086004 | 2022-04-11 | ||
| PCT/CN2022/091679 WO2022237720A1 (en) | 2021-05-11 | 2022-05-09 | Combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013410A true MX2023013410A (es) | 2023-12-06 |
Family
ID=81753154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013410A MX2023013410A (es) | 2021-05-11 | 2022-05-09 | Terapias de combinacion. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4337216A1 (https=) |
| JP (1) | JP2024518497A (https=) |
| KR (1) | KR20240006631A (https=) |
| CN (2) | CN117460513A (https=) |
| AU (1) | AU2022274071A1 (https=) |
| CA (1) | CA3215313A1 (https=) |
| CL (2) | CL2023003239A1 (https=) |
| CO (1) | CO2023014322A2 (https=) |
| DO (1) | DOP2023000246A (https=) |
| IL (1) | IL308335A (https=) |
| MX (1) | MX2023013410A (https=) |
| PE (1) | PE20240593A1 (https=) |
| PH (1) | PH12023552974A1 (https=) |
| TW (1) | TW202308643A (https=) |
| UY (1) | UY39761A (https=) |
| WO (1) | WO2022237720A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| EP4626426A1 (en) * | 2022-11-30 | 2025-10-08 | JANSSEN Pharmaceutica NV | Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent |
| WO2024114666A1 (en) * | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor |
| EP4698182A1 (en) * | 2023-04-17 | 2026-02-25 | Janssen Pharmaceutica NV | Combination of a menin-ll1 inhibitor, a dna intercalating agent and a pyrimidine analogue to treat a hematopoietic disorder |
| WO2025082444A2 (en) * | 2023-10-20 | 2025-04-24 | Janssen Pharmaceutica Nv | (r) -n-ethyl-5-fluoro-n-isopropyl-2- ( (5- (2- (6- ( (2-methoxyethyl) (methyl) amino) -2-methylhexan-3-yl) -2, 6-diazaspiro [3.4] octan-6-yl) -1, 2, 4-triazin-6-yl) oxy) benzamide, formulations and dosage regimens thereof, for use in treating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TN2017000080A1 (en) | 2014-12-18 | 2018-07-04 | Takeda Pharmaceuticals Co | Solid state forms of fused heteroaromatic pyrrolidinones |
| AU2016378579A1 (en) * | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| WO2017214367A1 (en) * | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| TW202104207A (zh) | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
-
2022
- 2022-05-09 MX MX2023013410A patent/MX2023013410A/es unknown
- 2022-05-09 KR KR1020237042402A patent/KR20240006631A/ko active Pending
- 2022-05-09 PH PH1/2023/552974A patent/PH12023552974A1/en unknown
- 2022-05-09 PE PE2023003030A patent/PE20240593A1/es unknown
- 2022-05-09 EP EP22725158.4A patent/EP4337216A1/en active Pending
- 2022-05-09 CA CA3215313A patent/CA3215313A1/en active Pending
- 2022-05-09 WO PCT/CN2022/091679 patent/WO2022237720A1/en not_active Ceased
- 2022-05-09 JP JP2023569789A patent/JP2024518497A/ja active Pending
- 2022-05-09 CN CN202280034525.XA patent/CN117460513A/zh active Pending
- 2022-05-09 CN CN202410897512.6A patent/CN118845787A/zh active Pending
- 2022-05-09 IL IL308335A patent/IL308335A/en unknown
- 2022-05-09 AU AU2022274071A patent/AU2022274071A1/en active Pending
- 2022-05-10 UY UY0001039761A patent/UY39761A/es unknown
- 2022-05-10 TW TW111117441A patent/TW202308643A/zh unknown
-
2023
- 2023-10-25 CO CONC2023/0014322A patent/CO2023014322A2/es unknown
- 2023-10-31 CL CL2023003239A patent/CL2023003239A1/es unknown
- 2023-11-08 DO DO2023000246A patent/DOP2023000246A/es unknown
-
2024
- 2024-09-23 CL CL2024002832A patent/CL2024002832A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022274071A1 (en) | 2024-01-04 |
| JP2024518497A (ja) | 2024-05-01 |
| CO2023014322A2 (es) | 2023-11-20 |
| DOP2023000246A (es) | 2024-04-30 |
| IL308335A (en) | 2024-01-01 |
| CL2024002832A1 (es) | 2025-02-14 |
| CA3215313A1 (en) | 2022-11-17 |
| PH12023552974A1 (en) | 2024-03-11 |
| CL2023003239A1 (es) | 2024-06-07 |
| PE20240593A1 (es) | 2024-03-21 |
| TW202308643A (zh) | 2023-03-01 |
| CN118845787A (zh) | 2024-10-29 |
| UY39761A (es) | 2022-11-30 |
| CN117460513A (zh) | 2024-01-26 |
| EP4337216A1 (en) | 2024-03-20 |
| WO2022237720A1 (en) | 2022-11-17 |
| KR20240006631A (ko) | 2024-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000246A (es) | Terapias de combinación | |
| CL2023000847A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| BR112022010377A2 (pt) | Novos tiromiméticos | |
| DOP2023000239A (es) | Terapias de combinacion | |
| MX2012001654A (es) | Metodos para usar moduladores de c-met. | |
| AR053026A1 (es) | Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf) | |
| AR122352A1 (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este | |
| CL2020003143A1 (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
| MX2024005670A (es) | Analogos deuterados de acetil-leucina. | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| MX2023010506A (es) | Composiciones que comprenden profarmacos de escision enzimatica y nafamostat de liberacion controlada y metodos de uso de estos. | |
| MX2020011367A (es) | Compuesto oxo-sustituido. | |
| CL2023003253A1 (es) | Moduladores de trex1 | |
| CO2025016753A2 (es) | Inhibidores de gsk3α y métodos de uso de estos | |
| MX2018014081A (es) | Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal. | |
| CL2023003168A1 (es) | Moduladores de trex1 | |
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| CL2021002144A1 (es) | Compuesto heterociclo pentacíclico. | |
| AR107310A1 (es) | Inhibidores de tetrahidrocarbazol de receptores sirt1 | |
| MX2022002000A (es) | Derivados de pirazol y uso de los mismos. | |
| AR046043A1 (es) | Asociacion de un agente anti-aterotrombotico y un agente anti-agregacion de plaquetas y composiciones farmaceuticas que los contienen | |
| MX2021015973A (es) | Compuesto novedoso de ester de fosfato que tiene esqueleto de pirrolopirimidina, o sal farmaceuticamente aceptable del mismo. | |
| AR099330A1 (es) | Uso de paricalcitol en el tratamiento de la anemia inflamatoria | |
| UY39308A (es) | Derivados de aminopirimidinilo |